Renoprotective effects of telmisartan in patients with advanced chronic kidney disease

Clinical Nephrology

Volumn 73, Issue 2, 2010, Pages 139-146

  Tokunaga, M ^a   Kabashima, N ^a   Serino, R ^a   Shibata, T ^a   Matsumoto, M ^a   Miyamoto, T ^a   Miyazaki, M ^a   Furuno, Y ^a   Nakamata, J ^a   Fujimoto, Y ^a   Takeuchi, M ^a   Abe, H ^a   Okazaki, M ^a   Otsuji, Y ^a   Tamura, M ^a  

^a School of Medicine   (Japan)

Author keywords

Adverse effect; Angiotensin II receptor blocker; Estimated glomerular filtration ratio; Proteinuria; Renoprotective effect; Telmisartan

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; TELMISARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEINURIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY;

EID: 76649114017     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73139     Document Type: Article

References (26)

1. Nickenig G, Ostergren J, Struijker-Boudier H. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J Renin Angiotensin Aldosterone Syst. 2006; 7 (Suppl): 1-7.
2. Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J Am Soc Nephrol. 2004; 15 (Suppl): 64-70.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. RENAAL Study Investigators. Effect of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869.
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med. 2001; 345: 851-860.
5. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, Matsui T, Jinnouchi Y, Imaizumi T. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res. 2005; 70: 137-141.
6. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized control trial. Lancet. 2003; 361: 117-124.
7. Parving HH, Lehnert H, Bronchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870-878.
8. Wang D, Chen Y, Chabrashvili T, Aslam S, Borrego Conde LJ, Umans JG, Wilcox CS. Role of oxidative stress in endothelial dysfunction and enhanced responses to angiotensin II of afferent arterioles from rabbits infused with angiotensin II. J Am Soc Nephrol. 2003; 14: 2783-2789.
9. Welch WJ, Blau J, Xie H, Chabrashvili T, Wilcox CS. Angiotensin-induced defects in renal oxygenation: role of oxidative stress. Am J Physiol Heart Circ Physiol. 2005; 288: 22-28.
10. Nakamura T, Kanno Y, Takenaka T, Suzuki H, for the Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res. 2005; 28: 415-423.
11. Takaya T, Kawashima S, Shinohara M, Yamashita T, Toh R, Sasaki N, Inoue N, Hirata K, Yokoyama M. Angiotensin II Type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. Atherosclerosis. 2006; 186: 402-410.
12. Morimoto S, Yano Y, Maki K, Sawada K. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res. 2006; 29: 567-572.
13. Tamura Y, Kosuga M, Yamashita M, Tomioka S, Sasaki M, Hikita T, Nakajima H, Kojima K, Uchida S. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with Stage 4-5 chronic kidney disease. Clin Exp Nephrol. 2008; 12: 256-263.
14. Stangier J, Schmid J, Türck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, Jonkman JH. Absorption, metabolism, and excretion of intravenously and orally administered (14C)telmisartan in healthy volunteers. J Clin Pharmacol. 2000; 40: 1312-1322.
15. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139: 137-147.
16. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int. 1998; 53: 1209-1216.
17. Ruggenenti P, Perna A, Remuzzi G, Gruppo Italiano di Studi Epiderminologici in Nefrologia. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. J Am Soc Nephrol. 2001; 12: 2832-2837.
18. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006; 3542: 131-140.
19. Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis. 1996; 27: 489-495.
20. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q, Salvadori M, Remuzzi G. In chronic nephropathies prolonged ACEinhibitor can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol. 1999; 10: 997-1006.
21. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.
22. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease study. Ann Intern Med. 1995; 123: 754-762.
23. Readon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998; 158: 26-32.
24. Reams GP, Bauer JH. Effects of lisinopril monotherapy on renal hemodyamics. Am J Kidney Dis. 1988; 11: 499-507.
25. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000; 160: 685-693.
26. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 932-935.